Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure

Hypertension

Volumn 64, Issue 6, 2014, Pages 1235-1240

  Ramirez, Claudia E ^a   Okamoto, Luis E ^a   Arnold, Amy C ^a   Gamboa, Alfredo ^a   Diedrich, André ^a   Choi, Leena ^b   Raj, Satish R ^a   Robertson, David ^a   Biaggioni, Italo ^a   Shibao, Cyndya A ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atomoxetine; Autonomic failure; Midodrine; Orthostatic hypotension

Indexed keywords

ATOMOXETINE; MIDODRINE; PLACEBO; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; PROPYLAMINE;

ADRENERGIC SYSTEM; AGED; ARTICLE; AUTONOMIC DYSFUNCTION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PRESSOR RESPONSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STANDING; SYSTOLIC BLOOD PRESSURE; BLOOD PRESSURE; BODY POSTURE; COMPLICATION; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; HYPOTENSION, ORTHOSTATIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PURE AUTONOMIC FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC UPTAKE INHIBITORS; AGED; BLOOD PRESSURE; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTENSION, ORTHOSTATIC; MALE; MIDDLE AGED; MIDODRINE; POSTURE; PROPYLAMINES; PURE AUTONOMIC FAILURE; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84922481877     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04225     Document Type: Article

References (38)

1. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13:930-936.
2. Shibao C, Lipsitz LA, Biaggioni I; American Society of Hypertension Writing Group. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013;7:317-324.
3. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, Rubin M, Fouad-Tarazi FM. Neurogenic orthostatic hypotension: a doubleblind, placebo-controlled study with midodrine. Am J Med. 1993;95:38-48.
4. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046-1051.
5. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, Low PA. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120-124.
6. Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010;304:2172-2173.
7. Walsh S. FDA Proposes Withdrawal of Low Blood Pressure Drug. US Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm222580.htm. Accessed April 22, 2013.
8. Diedrich A, Jordan J, Tank J, Shannon JR, Robertson R, Luft FC, Robertson D, Biaggioni I. The sympathetic nervous system in hypertension: assessment by blood pressure variability and ganglionic blockade. J Hypertens. 2003;21:1677-1686.
9. Shibao C, Okamoto L, Biaggioni I. Pharmacotherapy of autonomic failure. Pharmacol Ther. 2012;134:279-286.
10. Meredith IT, Esler MD, Cox HS, Lambert GW, Jennings GL, Eisenhofer G. Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clin Auton Res. 1991;1:187-194.
11. Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50:47-53.
12. Goldenberg MM. Pharmaceutical approval update. P T. 2014;39:337-344.
13. Mosqueda-Garcia R. Evaluation of the autonomic nervous system. In: Robertson D, Biaggioni I, eds. Disorders of the Autonomic Nervous System. London: Harwood Academy Press; 1995:25-29.
14. Robertson D. Clinical pharmacology: assessment of autonomic function. In: Baughman K, Greene B, eds. Clinical Diagnostic Manual for the House Officer. Baltimore, MD: William and Wilkins; 1981:86-101.
15. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21:69-72.
16. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22:79-90.
17. Witcher JW, Long A, Smith B, Sauer JM, Heilgenstein J, Wilens T, Spencer T, Biederman J. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2003;13:53-63.
18. Zachariah PK, Bloedow DC, Moyer TP, Sheps SG, Schirger A, Fealey RD. Pharmacodynamics of midodrine, an antihypotensive agent. Clin Pharmacol Ther. 1986;39:586-591.
19. Chelsea Therapeutics, Inc. NortheraTM (Droxidopa) Advisory Committee Briefing Document. US Food and Drug Administration. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm381155.pdf. Accessed March 11, 2014.
20. Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990;11:116-128.
21. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, O'Brien PC, Slezak J, Low PA. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63:513-518.
22. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
23. Mao AR, Babcock T, Brams M. ADHD in adults: current treatment trends with consideration of abuse potential of medications. J Psychiatr Pract. 2011;17:241-250.
24. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-1904.
25. Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich). 2013;15:147-153.
26. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alphaadrenergic agonist (midodrine). Neurology. 1988;38:951-956.
27. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99:604-610.
28. Shibao C, Grijalva CG, Lipsitz LA, Biaggioni I, Griffin MR. Early discontinuation of treatment in patients with orthostatic hypotension. Auton Neurosci. 2013;177:291-296.
29. Novak V, Novak P, Spies JM, Low PA. Autoregulation of cerebral blood fow in orthostatic hypotension. Stroke. 1998;29:104-111.
30. Matsubara S, Sawa Y, Yokoji H, Takamori M. Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3, 4-dihydroxyphenylserine on the blood pressure and regional cerebral blood fow. J Neurol Neurosurg Psychiatry. 1990;53:994-997.
31. Marquand AF, O'Daly OG, De Simoni S, Alsop DC, Maguire RP, Williams SC, Zelaya FO, Mehta MA. Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood fow in healthy volunteers at rest: a multi-class pattern recognition approach. Neuroimage. 2012;60:1015-1024.
32. Robertson D, Hollister AS, Carey EL, Tung CS, Goldberg MR, Robertson RM. Increased vascular beta2-adrenoceptor responsiveness in autonomic dysfunction. J Am Coll Cardiol. 1984;3:850-856.
33. Osswald W. Transmitter disposition mechanisms. In: Bevan J, Johansson B, Nedergaard O, eds. Vascular Neuroeffector Mechanisms. Basel: Karger; 1976:123-130.
34. Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006;47:522-526.
35. Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain. 2012;135(Pt 6):1900-1913.
36. Benarroch EE, Smithson IL, Low PA, Parisi JE. Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure. Ann Neurol. 1998;43:156-163.
37. Küpfer A, Preisig R. Inherited defects of hepatic drug metabolism. Semin Liver Dis. 1983;3:341-354.
38. Price-Evans D. Therapy. In: Kalow W, Goedde H, Agarwal D, eds. Ethnic Differences in Reaction to Drug and Xenobiotics. New York: Liss; 1986:491-526.